Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) AI Stock Analysis

• Market Cap: HK$1.53B
• Dividend Yield: N/A
• Average Volume (3M): 682.20K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.54
• Revenue Growth: N/A
• EPS Growth: 50.94%
• Country: HK
• Employees: 63
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 236,223,330
• 10 Day Avg. Volume: 1,378,920
• 30 Day Avg. Volume: 682,196
• PEG Ratio: 0.12
• Price to Book (P/B): 1.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 32 Underperform
• Price Target: ―

The overall score reflects significant financial challenges, with the absence of revenue and consistent net losses being the primary concerns. Technical analysis indicates recent weakness, though some longer-term price stability is noted. Valuation metrics remain poor due to the company's ongoing losses. Overall, the stock is highly speculative and carries substantial risk, typical of early-stage biotech firms.

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) is a biotechnology company that specializes in the research, development, and commercialization of innovative medical devices and technologies. Primarily operating in the healthcare sector, the company focuses on products that address cardiovascular diseases. Its core offerings include advanced therapeutic solutions and diagnostic tools designed to improve patient outcomes and enhance the efficiency of healthcare delivery.

How the Company Makes Money

Shanghai Bio-Heart Biological Technology Co., Ltd. generates revenue by developing and selling medical devices and technologies related to cardiovascular health. The company earns income through the sale of its proprietary products to healthcare providers, hospitals, and clinics. Additionally, it may engage in partnerships or licensing agreements with other medical technology firms or research institutions to co-develop new products or expand market reach. Revenues are also supported by ongoing research and development efforts that lead to new innovations and solutions in the cardiovascular sector.

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Financial Statement Overview

Summary

Shanghai Bio-Heart Biological Technology Co., Ltd. faces significant financial challenges typical of early-stage biotech firms. With zero revenue, the company consistently reports net losses. Despite a strong equity base and low leverage, the persistent negative cash flows and absence of revenue-generating activities are major financial risks.

Income Statement

The company has consistently reported zero revenue across all periods, resulting in negative gross profit, EBIT, and net income. This indicates a lack of revenue-generating activities, which is critical for sustainability and profitability. The persistent net losses highlight a significant financial risk, typical for early-stage biotech firms without marketable products.

Balance Sheet

The company maintains a strong equity base, with stockholders' equity consistently exceeding total liabilities, resulting in a healthy equity ratio. The debt-to-equity ratio is low, indicating minimal reliance on debt financing. However, the shrinking total assets and equity over time suggest potential financial strain if revenue generation does not commence.

Cash Flow

Operating and free cash flows are consistently negative, reflecting ongoing operational challenges and a cash burn typical of biotech firms in the pre-revenue stage. The lack of free cash flow growth and negative operating cash flow relative to net income highlight cash management risks.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-23.60M	-24.25M	-15.95M	-9.71M
	EBIT
-61.04M	-164.62M	-293.28M	-493.72M	-368.05M
	EBITDA
-44.54M	-158.31M	-209.05M	-477.77M	-358.34M
	Net Income Common Stockholders
-87.94M	-194.36M	-237.50M	-435.62M	-365.79M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
202.39M	369.44M	506.71M	866.72M	537.89M
	Total Assets
733.78M	817.90M	1.10B	1.36B	930.78M
	Total Debt
8.28M	1.76M	20.33M	27.46M	1.56M
	Net Debt
-194.10M	-367.68M	-486.39M	-839.26M	-536.33M
	Total Liabilities
53.24M	44.04M	67.27M	88.72M	40.94M
	Stockholders Equity
660.47M	748.41M	991.62M	1.22B	830.05M
Cash Flow		Free Cash Flow
0.00	-67.00M	-193.79M	-147.28M	-60.74M
	Operating Cash Flow
0.00	-49.03M	-158.86M	-105.45M	-54.28M
	Investing Cash Flow
0.00	-28.86M	-121.75M	-41.83M	-253.21M
	Financing Cash Flow
0.00	-5.82M	-40.91M	462.42M	812.42M

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.66
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2185, the sentiment is Positive. The current price of 3.66 is above the 20-day moving average (MA) of 3.23, above the 50-day MA of 2.70, and above the 200-day MA of 2.07, indicating a bullish trend. The MACD of 0.33 indicates Negative momentum. The RSI at 63.75 is Neutral, neither overbought nor oversold. The STOCH value of 43.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2185.

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2269	74 Outperform	$98.06B	27.18	8.17%	―	7.52%	-1.92%
2196	65 Neutral	$65.06B	13.78	6.22%	1.93%	-2.82%	11.93%
Sector *	59 Neutral	HK$14.51B	6.14	-7.38%	5.61%	12.00%	-20.84%
9926	55 Neutral	HK$81.95B	―	-8.98%	―	-54.66%	-123.11%
1877	52 Neutral	HK$32.10B	―	-19.78%	―	25.96%	39.58%
6185	48 Neutral	HK$10.78B	―	-4.41%	―	94.98%	85.69%
2185	32 Underperform	HK$1.53B	―	-12.49%	―	―	50.94%

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Corporate Events

Shanghai Bio-heart Launches Clinical Trial for Sirolimus DCB in Japan

Shanghai Bio-heart Biological Technology Co., Ltd. has initiated its SAKURA-SCB clinical trial in Japan, enrolling the first patient to evaluate a new sirolimus drug-coated balloon (DCB) for ischemic heart disease. This product aims to offer a safer alternative to existing paclitaxel-based treatments by utilizing sirolimus for its anti-inflammatory and cytostatic effects, potentially improving therapeutic outcomes and reducing restenosis.

Shanghai Bio-Heart Reports Reduced Losses and Key Milestones in 2024

Shanghai Bio-Heart Biological Technology Co., Ltd. reported a significant reduction in net loss for the year ended December 31, 2024, with a 50.6% decrease from the previous year. The company’s research and development expenses also saw a substantial decline of 63%, reflecting a strategic shift or efficiency improvements. Notably, the Iberis® RDN system received approval from the NMPA for treating resistant hypertension and completed its first commercial procedure in Europe, marking a significant milestone in its market expansion efforts.

Shanghai Bio-Heart Announces Board Composition and Roles

Shanghai Bio-Heart Biological Technology Co., Ltd. has announced the composition of its board of directors and their respective roles within the company. This announcement provides clarity on the governance structure, which is crucial for stakeholders to understand the leadership dynamics and decision-making processes within the company.

Shanghai Bio-Heart Forms Nomination Committee to Enhance Board Governance

Shanghai Bio-Heart Biological Technology Co., Ltd. has established a Nomination Committee to oversee the structure and composition of its Board of Directors. The committee is tasked with reviewing board diversity, assessing director independence, and making recommendations for board appointments and succession planning, thereby aligning with the company’s corporate strategy and enhancing governance practices.

Shanghai Bio-heart Schedules Board Meeting to Review Annual Results

Shanghai Bio-heart Biological Technology Co., Ltd. has scheduled a board meeting on March 28, 2025, to consider and approve the company’s annual results for the year ending December 31, 2024, and to discuss the potential recommendation of a final dividend. This meeting is significant as it will determine the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.

Shanghai Bio-Heart Launches Iberis® RDN System in Europe

Shanghai Bio-Heart Biological Technology Co., Ltd. announced the completion of the first commercial procedure of its Iberis® RDN system in Germany, marking a significant milestone in its European operations. The system, which offers a safer and more effective transradial approach for renal denervation, is the only globally approved product for both transradial and transfemoral approaches. This advancement enhances the company’s market positioning and expands its reach in the cardiovascular treatment sector, potentially impacting stakeholders positively by offering a less invasive treatment option for hypertension.

Shanghai Bio-heart’s Iberis® RDN System Gains NMPA Approval

Shanghai Bio-heart Biological Technology Co., Ltd. announced that its Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System has received approval from China’s National Medical Products Administration for treating resistant hypertension and hypertension patients with drug intolerance. This approval marks a significant milestone for the company, enhancing its market position and potentially impacting stakeholders positively. The Iberis-HTN trial demonstrated the system’s efficacy and safety, showing significant improvements in blood pressure management compared to control groups.

Shanghai Bio-Heart Approves Strategic Resolutions During Recent Meetings

Shanghai Bio-Heart Biological Technology Co., Ltd. successfully conducted its Extraordinary General Meeting and Class Meetings, passing all proposed resolutions. This includes a major transaction involving the deemed disposal of equity interest in a subsidiary and amendments to the company’s articles of association, reflecting strategic shifts and governance updates that may influence its operational and market strategy.